IRF2 and colorectal carcinoma: J. Ott and colleagues identified a SE-based CRC in chronic lymphocytic leukemia (CLL) involving PAX5, FOXP1, RARA, ETS1, IRF2, and IRF8, highlighting PAX5's dominant role.